-
A New Milestone in Prostate Cancer Treatment: FDA Approves Pluvicto for mHSPC
Expanding Options for Patients The landscape for treating prostate cancer has reached a significant turning point. The FDA has officially approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC). Understanding the Treatment Pluvicto is a targeted radioligand therapy. This means it…
-
A Significant Step Forward: First U.S. Patient Enrolled in BiPASS Phase 3 Study for Prostate Cancer Diagnosis
NASDAQ: $TLX Today marks an important milestone in the ongoing effort to improve the diagnosis and management of prostate cancer. We are excited to share news regarding the initiation of dosing for the first U.S. patient in the pivotal BiPASS Phase 3 clinical trial. This study focuses on assessing the performance of a novel diagnostic…